Par Sues UCB Over Generic Keppra

Law360, New York (March 25, 2011, 2:04 PM EDT) -- Par Pharmaceutical Cos. Inc. filed suit Wednesday in Pennsylvania seeking declaratory judgment that its proposed generic version of epilepsy treatment Keppra XR doesn't infringe UCB Pharma SA's patents covering the drug.

Par's submission of an abbreviated new drug application for permission to manufacture generic oral levetiracetam extended release tablets does not infringe U.S. Patent Numbers 7,858,122 and 7,863,316 because the patents are invalid and unenforceable, the plaintiff claims in a complaint filed in the U.S. District Court for the Eastern District of Pennsylvania.

The asserted patents,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.